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Simple Summary: The predominant histologic type of bladder cancer is urothelial carcinoma 
(UC).Programmed cell death-ligand 1 (PD-L1) expression levels in UC tumors help clinicians deter-
mine which patients are more likely to respond to immuno-oncology (IO) therapies; as such, the 
harmonization of PD-L1 testing in evaluating patients is increasingly important. A series of inter-
national workshops, involving renowned pathologists and oncologists, were held to develop best 
practice approaches to PD-L1 testing in UC. It was agreed that robust control of analytical standards 
is required to obtain quality PD-L1 results and that interpretation and reporting of PD-L1 require 
clear inter-clinician communication. Recommendations for the best practices for PD-L1 testing in 
UC are provided. A PD-L1 test request form for pathology laboratories was also developed and 
included here, encouraging communication between clinicians and pathologists, and ensuring fast 
and high-quality test results. Novel biomarkers being evaluated for immuno-oncology agents in UC 
are also briefly discussed. 
Abstract: Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–pro-
grammed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for meta-
static UC. PD-L1 expression levels in UC tumors help clinicians determine which patients are more 
likely to respond to IO therapies. Assays for approved IO agents use different antibodies, immuno-
histochemical protocols, cutoffs (defining “high” vs. “low” PD-L1 expression), and scoring algo-
rithms. The robust control of pre-analytical and analytical standards is needed to obtain high-qual-
ity PD-L1 results. To better understand the status and perspectives of biomarker-guided patient 
selection for anti–PD-1 and anti–PD-L1 agents in UC, three workshops were held from December 
2018 to December 2019 in Italy, Malaysia, and Spain. The primary goal was to develop recommen-
dations for best practice approaches to PD-L1 testing in UC. Recommendations pertaining to the 
interpretation and reporting of the results of PD-L1 assays from experienced pathologists and on-
cologists from around the globe are included. A test request form for pathology laboratories was 
developed as a critical first step for oncologists/urologists to encourage communication between 
clinicians and pathologists, ensuring fast and high-quality test results. In this era of personalized 
medicine, we briefly discuss novel biomarkers being evaluated for IO agents in UC. 
Keywords: assays; best practice; biomarkers; PD-L1; urothelial carcinoma 
 
Citation: Lopez-Beltran, A.;  
López-Rios, F.; Montironi, R.; 
Wildsmith, S.; and Eckstein, M. Im-
mune Checkpoint Inhibitors in 
Urothelial Carcinoma: Recommen-
dations for Practical Approaches to 
PD-L1 and Other Potential Predic-
tive Biomarker Testing. Cancers 2021, 
13, 1424. https://doi.org/10.3390/can-
cers13061424 
Academic Editor: Ronald de Wit 
Received: 9 February 2021 
Accepted: 18 March 2021 
Published: 20 March 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and insti-
tutional affiliations. 
 
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (http://crea-
tivecommons.org/licenses/by/4.0/). 




The predominant histologic type of bladder cancer is urothelial carcinoma (UC), ac-
counting for more than 90% of all cases [1]. UC is a heterogeneous disease that has histor-
ically been categorized into two distinct entities based on histologic features and genetic 
alterations—papillary non–muscle-invasive tumors (arising from epithelial hyperplasia 
sequence) and muscle-invasive tumors (arising from a dysplasia/carcinoma in situ se-
quence). However, more recently, comprehensive RNA expression profiling studies have 
identified at least five subtypes, the most fundamental division being basal/squamous-
like and luminal [2]. Approximately 70% of patients are diagnosed with non–muscle-in-
vasive tumors that infrequently metastasize, whereas 25% of patients are diagnosed with 
muscle-invasive tumors, of which approximately 40% will metastasize; 5% of patients are 
initially diagnosed with metastatic disease [3]. 
Although UC is mostly observed in its pure or conventional form, several histologic 
variants of invasive disease are now recognized by the World Health Organization, which 
arise from the propensity of UC for divergent differentiation [1,4]. While it is not com-
pletely understood how the different variants of UC affect prognosis, a greater under-
standing of the biology of UC has led to breakthrough treatments for metastatic disease. 
In particular, immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and 
anti–programmed cell death-ligand 1 (PD-L1)) have been studied as first- and second-line 
treatments for metastatic UC [5–8]. PD-L1 expression levels in UC tumors also help clini-
cians determine which patients are more likely to respond to IO therapies. Multiple assays 
approved for use with these IO agents use different antibodies, immunohistochemical 
(IHC) protocols, cutoffs (to define “high” vs. “low” PD-L1 expression), and scoring algo-
rithms [9]. 
To understand better the current status and perspectives of biomarker-guided pa-
tient selection for anti–PD-1 and anti–PD-L1 agents in UC, three workshops were held 
from December 2018 to December 2019 in Milan, Italy; Kuala Lumpur, Malaysia; and Ma-
drid, Spain. Here, we report the findings from these workshops, the primary goal of which 
was to develop a set of best practice recommendations for PD-L1 testing in UC. We in-
clude recommendations pertaining to the interpretation and reporting of the results of 
PD-L1 assays from renowned pathologists and oncologists from around the globe. Fur-
thermore, in this era of personalized medicine, we briefly discussed novel biomarkers be-
ing evaluated for IO agents in UC and introduced the concept of developing a master 
protocol to integrate these biomarkers into UC treatment regimens in the future. 
2. Current Treatment Landscape for UC 
The immune sensitivity of bladder cancer has been recognized since the 1970s when 
intravesical bacillus Calmette–Guérin was discovered [10], which, along with tran-
surethral resection of bladder tumor (TURB), remains today as the standard of care (SoC) 
for non–muscle-invasive disease in patients with high grade and/or T1 tumors [3], in pa-
tients with Ta high-grade tumors, mitomycin is an additional treatment option [11]. Treat-
ment of muscle-invasive bladder cancer includes surgery (radical cystectomy) with or 
without neoadjuvant chemotherapy, and patients at high risk of recurrence may be 
treated with adjuvant chemotherapy [12]. For the first-line treatment of unresectable, met-
astatic UC, platinum-based chemotherapy has remained the SoC for more than two dec-
ades [13]. Eligible patients can receive cisplatin-based regimens, most commonly gemcita-
bine plus cisplatin. Patients unable to receive cisplatin (approximately 50%) often receive 
gemcitabine plus carboplatin [14]. 
It has been shown that the number of tumor-infiltrating lymphocytes is lower in more 
advanced, metastasizing UC [15–18], with lower numbers of CD4+ T cells being particu-
larly associated with a poor prognosis [19]; thus, IO agents may be effective in restoring 
the immune response dampened by tumor immunosuppressive mechanisms. Indeed, the 
anti–PD-L1 agents atezolizumab, avelumab, and durvalumab and the anti–PD-1 agents 
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pembrolizumab and nivolumab are currently, or were previously, approved by the US 
Food and Drug Administration (FDA) for second-line treatment of advanced UC [20–24]. 
The approvals are regardless of PD-L1 status [5], although US FDA- and Conformitè Eu-
ropëenne (CE)-approved in vitro diagnostic device tests have been available since 2017 to 
inform physician decisions. The treatment landscape changed in 2017 when two of the IO 
agents were approved for the first-line treatment of metastatic UC in cisplatin-ineligible 
patients. Pembrolizumab [23] and atezolizumab were approved by the US FDA for the 
first-line treatment of cisplatin-ineligible patients with stage IV UC and high tumor PD-
L1 expression, or for patients not eligible for any platinum-based therapy regardless of 
PD-L1 status; subsequent to accelerated approval, both therapies were restricted for use 
in PD-L1–high patients based on data from ongoing studies. The accelerated approvals 
were based on single-arm, phase II studies with objective response rate by response eval-
uation criteria in Solid Tumors version 1.1 as the primary endpoints [25,26]. The European 
Medicines Agency (EMA) has approved atezolizumab and pembrolizumab for first-line 
treatment of cisplatin-ineligible patients with stage IV UC and high tumor PD-L1 expres-
sion. More recently, avelumab combined with best supportive care (BSC) demonstrated 
an improvement in overall survival (OS) versus BSC alone in patients who had not pro-
gressed following chemotherapy for advanced UC. Patients who did not progress were 
enrolled in the trial. Survival was higher in patients with tumors expressing PD-L1, as 
measured using the VENTANA PD-L1 (SP263) Assay [27]. 
The efficacy of IO agents in metastatic UC has prompted investigators to evaluate the 
potential of these therapies in earlier stages of the disease, i.e., non–muscle-invasive tu-
mors and in the neoadjuvant and adjuvant settings for localized muscle-invasive bladder 
cancer [28–30]. Collectively, there is increasing use of anti–PD-1 and anti–PD-L1 agents 
for the treatment of UC across disease stages, underscoring the role of PD-L1 testing in 
evaluating patients. 
3. The Role of PD-L1 in UC 
It is well established that PD-L1 on tumor cells (TCs) inhibits the antitumor responses 
of PD-1-expressing CD8+ T cells [31]. However, PD-L1 expression on immune cells (ICs) 
(e.g., tumor-associated macrophages) may also be important for the escape of TCs from 
immune detection [32], particularly for more immunogenic tumors such as UC [9]. The 
expression of PD-L1 on ICs appears to be of greater magnitude and of longer duration 
than on TCs and PD-L1 expression is IFNγ-dependent in TCs but only partially IFNγ-
dependent in ICs [9,32], suggesting that the majority of PD-L1 in the immunosuppressive 
tumor microenvironment may be provided by ICs [32]. 
DNA (promoter) methylation regulates the expression of PD-L1 and is associated 
with interferon signaling transcriptional phenotype [33]. PD-L1 promoter methylation, 
resulting in down-regulation of expression, may be a mechanism of resistance to anti–PD-
1 and anti–PD-L1 agents [34]. Several studies have evaluated the prognostic value of PD-
L1 expression [9,16,35,36]. Mixed results have been reported, but most studies have shown 
a poorer prognosis for patients with high TC PD-L1 expression [16,37–41], and conversely, 
higher IC PD-L1 expression is associated with a better prognosis in metastatic UC 
[9,16,42]. The positive prognostic role of PD-L1 expression on ICs is supported by the out-
come of phase III IMvigor130 trial; using an IC-only algorithm, patients with high PD-L1 
(IC ≥ 5%) treated with both atezolizumab and SoC had higher survival than all-comers 
[43]. Conversely, in the KEYNOTE-052 trial, in which a combined TC and IC algorithm 
was used (combined positive score (CPS) ≥ 10), survival was lower in the patients with 
high PD-L1 than all-comers in both the pembrolizumab and SoC arms [25]. 
The role of PD-L1 in predicting outcomes with anti–PD-1 and anti–PD-L1 agents has 
yielded mixed results [9]. A meta-analysis of 10 studies with immune checkpoint inhibi-
tors (prior to 2018) concluded that PD-L1 expression was associated with objective re-
sponse rates but not OS [5]. More recently, the data from phase III randomized controlled 
trials have highlighted variability in the ability of PD-L1 to predict outcomes, particularly 
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for IC-only approaches. For example, patients with high PD-L1 expression (IC ≥ 5%) in 
the IMvigor130 trial showed improved survival over those with low expression (median 
OS not estimable vs. 13.5 months) [44], whereas lower survival was seen in PD-L1–high 
patients than PD-L1 low/negative patients in IMvigor210 (median OS 12.3 months vs. 19.1 
months) [26]. In the IMvigor10 trial, in high-risk patients with muscle-invasive bladder 
cancer (MIBC), PD-L1 expression did not enrich for disease-free survival (hazard ratio 
(HR) 1.01 vs. HR 0.81 in PD-L1 high vs. low/negatives) [28]. Using both TC and IC PD-L1 
expression, the CPS assay predicted improved survival in pembrolizumab-treated pa-
tients in the KEYNOTE-045 (HR 0.73 vs. 0.57) [35] and KEYNOTE-052 trials (median OS 
12.3 months vs. 18.5 months) [45]. Similarly, recent data from the JAVELIN Bladder 100 
trial of maintenance therapy showed improved survival in the PD-L1 high versus all-com-
ers (HR 0.56 vs. 0.69). This indicates that the PD-L1 assay with a TC/IC ≥ 25 algorithm is 
predictive, although expression data were incomplete [27]. The utility of PD-L1 for pre-
dicting response in non-small cell lung cancer has been demonstrated, mainly by as-
sessing PD-L1 on TCs, the result of which indicated significant levels of expression. How-
ever, in UC, the expression on ICs predominates [46]. This differential pattern of PD-L1 
expression may explain differences in predictive utility. There is also evidence that PD-L1 
expression may be prognostic in UC, which has the potential to confound predictive ef-
fects [36]. 
4. Evaluation of PD-L1 in UC 
Five validated, commercial assays are available to assess PD-L1 expression on TCs 
and ICs for approved anti–PD-1 and anti–PD-L1 agents (Table 1) [9,47,48], of which four 
are FDA approved (pharmDX 73-10 is not FDA approved; Table 1). These assays use dif-
ferent antibodies, IHC protocols, cutoffs (to define “high” vs. “low” PD-L1 expression), 
and scoring algorithms, the latter of which varies widely across assays in UC. Each algo-
rithm and cutpoint was independently developed using clinical data from a therapy to 
best identify patients who would benefit; although the PD-L1 antibody stains may be sim-
ilar, the algorithms are unique to each drug. Often, the cutpoints were determined using 
limited patient numbers, single-arm trials, and response data. Later in development, OS 
data may support the choice of the optimal cutpoint [49]. The different scoring algorithms 
for the companion diagnostic assays of validated or approved IO agents are summarized 
in Table 1 [50–53]. 
PD-L1 testing in conjunction with pembrolizumab in UC (PD-L1 IHC pharmDx 22C3 
assay) is based on the combination of the total number of TCs and ICs with PD-L1 staining 
as a proportion of the total number of TCs (CPS); for TC scoring with nivolumab (PD-L1 
IHC pharmDx 28-8 Assay), durvalumab (VENTANA PD-L1 (SP263) Assay), and 
avelumab (PD-L1 IHC pharmDx 73-10 Assay) the proportion of TCs with PD-L1 staining 
per TC area is assessed; with durvalumab (VENTANA PD-L1 (SP263) Assay) the propor-
tion of ICs with PD-L1 staining within the total IC area is used; with atezolizumab (VEN-
TANA PD-L1 (SP142) Assay), the proportion of the tumor area occupied by PD-L1 stained 
ICs is measured. It is important to note when reporting scoring that the method of scoring 
ICs is different for durvalumab (VENTANA PD-L1 (SP263) Assay) and atezolizumab 
(VENTANA PD-L1 (SP142) Assay). Examples of IC and TC PD-L1 staining in UC using 
the VENTANA PD-L1 (SP263) Assay are provided in Figure 1. 
Preliminary findings suggest that it may be feasible to measure PD-L1 in circulating 
tumor cells (CTCs). However, these methods would not include PD-L1 expression on tu-
mor-infiltrating ICs and the reproducibility and clinical utility of these assays remain to 
be proven [54]. 




Figure 1. (A,B). Examples of immune cell (IC) and tumor cell (TC) programmed cell death-ligand 1 
(PD-L1) staining in urothelial carcinoma (UC) using the VENTANA PD-L1 (SP263) Assay (Images 
provided by Marietta Scott, Precision Medicine & Biosamples, AstraZeneca). 
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Table 1. Scoring algorithms for the companion diagnostic assays of immuno-oncology (IO) agents. 
Anti–PD-1/PD-L1 Ther-
apeutics 
Atezolizumab Avelumab Durvalumab, Avelumab, and Tislelizumab Nivolumab Pembrolizumab 
Assay 
VENTANA PD-L1 (SP142) Assay 
[52] 
PD-L1 IHC pharmDx 
73-10  
[not FDA approved] 
VENTANA PD-L1 (SP263) Assay [53] 
PD-L1 IHC pharmDx 28-
8 [50] 
PD-L1 IHC pharmDx 22C3 
[51] 
Scoring algorithm 
IC ≥ 5%; number of PD-L1–positive 
tumor-infiltrating ICs as a propor-
tion of the total TC and IC area 
TC ≥ 5%; number of 
PD-L1–positive TCs as 
a proportion of the to-
tal TC area 
TC or IC ≥ 25%; number of PD-L1–positive TCs with 
membrane staining as a proportion of the total TC 
area or PD-L1–positive ICs with membrane, cyto-
plasm, or punctate as a proportion of the total IC 
area. 
TC ≥ 1%; number of PD-
L1–positive TCs as a 
proportion of the total 
TC area 
Number (Count) of PD-
L1–positive TCs and num-
ber of PD-L1–positive ICs 
as a proportion of the total 
TC area 
Typical staining  
characteristics 
Dot-/ant-like staining pattern 
Low tumor cell staining 
Strong IC staining 
Developed for immune cell scoring 
 
Homogenous tumor cell staining 
Mostly strong staining intensity for TCs and ICs 




Homogenous tumor cell 
staining 
Mostly weak staining in-
tensity 
Design Considerations 
Plasma cells have to be excluded 
from scoring 
All immune cells are included (incl. 
neutrophil granulocytes) 
 
Immune cell positivity is scored according to the 
area occupied by all immune cells  
(IC-“Area”-score) 
TC and IC are scored independently. Patients are 
positive when exceeding one of the two cutoffs or 
both 
PD-L1 can also be considered high if: 
ICP * > 1% and IC+ ≥ 25%; or, 
ICP * = 1% and IC+ = 100%. 
Plasma cells have to be excluded from scoring 
All immune cells are included (incl. neutrophil gran-
ulocytes) 
 
Combined positive score 
including immune cells 
and tumor cells 
Plasma cells have to be ex-
cluded from scoring 
Neutrophil granulocytes 
not included 
* ICP, tumor-associated immune cells in the tumor area.
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5. Methodological Considerations 
5.1. Pre-Analytics 
Robust control of pre-analytical and analytical standards is needed to obtain high-
quality PD-L1 results. Given the number of companion PD-L1 assays available, a test re-
quest form for pathology laboratories is a critical first step for oncologists/urologists [55]. 
The initial exchange of information between oncologists/urologists and pathologists is ex-
tremely important to determine the specific IO therapy for a given patient. We, therefore, 
recommend the use of the PD-L1 test request form that requires input from both clinicians 
and pathologists, as shown in Figure 2. 
 
Figure 2. Example of a PD-L1 test request form. 
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There are two ways to approach the scoring algorithm using the test request form, 
and the appropriate approach should be chosen for each institution. In the first approach, 
the clinician chooses an IO therapy and then informs the pathologist in order to match the 
scoring algorithm to the preferred IO therapy. Using the second approach, the pathologist 
would report the results of all scoring algorithms, and then the clinician makes an in-
formed decision regarding the IO therapy based on the “best” scoring algorithm. 
It should be noted that the differences in the approved assays mean that different 
PD-L1 classifications are likely, i.e., a patient with metastatic UC may be eligible for first-
line treatment with one agent but not with another. For instance, discordance in the selec-
tion of populations between the VENTANA PD-L1 (SP142) Assay and the PD-L1 IHC 
pharmDx 22C3 Assay was reported in approximately 42% of patients who were PD-L1 
positive by at least one of the assays [56], and fewer patients are deemed eligible for first-
line treatment with an IO agent based on the SP142 assay [56]. An assay comparison study, 
in which UC tumor samples were stained and scored with the algorithm and cutpoint 
associated with that assay, demonstrated the overlap of positive cases using commercially 
available PD-L1 assays (Figure 3) [48]. 
 
Figure 3. UC specimens classified as PD-L1 high using commercially available PD-L1 assays. The 
figure shows the overlap of positive cases using three commercially available PD-L1 assays. In an 
assay comparison study, 335 UC tumor samples were stained and scored with the algorithm and 
cutpoint associated with that assay [48]. Of the 40% of samples deemed PD-L1 high using any assay, 
12% were uniquely identified by the VENTANA PD-L1 (SP263) Assay, 5% by the PD-L1 IHC phar-
mDx 22C3 Assay, and none were unique to the VENTANA PD-L1 (SP142) Assay. The highest over-
lap in assays was observed between the VENTANA PD-L1 (SP263) Assay and PD-L1 IHC pharmDx 
22C3 Assay, where 22% of samples were PD-L1 high with either assay. If extrapolated to a clinical 
setting, this exploratory study indicates that of 100 patients tested with all three assays, only four 
patients would be deemed PD-L1 high with all three assays (with acknowledgment to Marietta 
Scott, Precision Medicine, AstraZeneca, Cambridge, UK, for analysis of the data). 
Pathologists may have several sample types available for analysis, including biopsy 
(lymph nodes and metastatic tissue), TURB, and cystectomy specimens. In all cases, it is 
important to fix the specimen as soon as possible and within a maximum of 30 min after 
biopsy/resection. This may require significant coordination between the pathologist and 
surgeon, for example, for specimens obtained from resections or cystectomies. At present, 
there are limited data regarding differences in sample type for the assessment of PD-L1 
using the available IHC assays. Based on our combined experience, our recommendations 
Cancers 2021, 13, 1424 9 of 18 
 
 
for the optimal conditions for PD-L1 immunohistochemistry are described in Table 2 
[57,58]. 
Table 2. Recommendations for optimal conditions for PD-L1 immunohistochemistry. 
Specimen Selection Recommendations for Optimum Conditions * 
Site of biopsy Use biopsies from a sample relevant to the disease stage, e.g., TURBS for MIBC, primary/metastatic for mUC. 
Specimen age 
Use formalin-fixed, paraffin-embedded sample blocks which have not been subjected to warm or fluctuating tem-
peratures. 
Use the most recent sample proximal to starting therapy (maximum of 1 year old) [55]. 
When using approved assays follow the manufacturer’s instructions as cut slide stability can range from 1 to 6 
months (PD-L1 IHC pharmDx 22C3 PI [51] and VENTANA PD-L1 (SP263) PI [58]). 
Specimen type 
Score the whole slide. 
Select a tissue specimen with invasive disease. ** TURB samples may be considered, however, only if they contain 
the invasive disease. 
Avoid highly necrotic samples where possible. 
Use positive controls for PD-L1; lymphatic tonsil tissue is recommended as optimal, with positive staining for mac-
rophages, dendritic cells, and lymphocytes. 
Do not use cytology/smears for scoring ICs, as tissue architecture is necessary to understand if ICs are tumor infil-
trating. 
It is currently not generally advised to use samples of bone metastases. 
There is however some evidence that bone decalcification using EDTA solution may yield good results and could 
possibly be used for PD-L1 IHC. Validation is required. 
Sample preparation/fixation 
Use 10% neutral buffered formalin in a quantity > 10 times the volume of the specimen. 
Sample should be placed in formalin as soon as possible (<30 min) and for a period of 12–24 h. Longer fixation may 
cause diffuse staining patterns. 
For immunohistochemistry, fixation should be performed for a minimum of 6 h and no more than 72 h. 
Large samples should be excised to allow for sufficient penetration of the fixative. 
Fixative penetrates about 1 mm/h with slight variation across different types of tissues. 
i.e., for cystectomy samples, the tumor should be excised, or the bladder opened to allow fixative to penetrate. 
Avoid decalcified tissue or tissue processed with other fixatives. 
Use on-slide positive and negative controls from the same institution or manufacturer, especially if an automated 
stainer is not used. 
Section specimens into a thickness of 3 or 4 µmm (as specified in manufacturers instruction). 
* Author recommendations only; please refer to the manufacturers' package insert instructions for the licensed use (VENTANA PD-L1 
(SP263) Assay PI [58] and VENTANA PD-L1 (SP142) Assay PI [57]). ** As most IO agents are currently only approved for locally advanced 
or metastatic UC (except for pembrolizumab, which is also approved for non–muscle-invasive bladder cancer in the USA), we recommend 
selecting a tissue specimen with invasive disease, rather than TURB. 
5.2. Analytics 
Challenges faced by pathologists for PD-L1 testing are both biological and technical. 
Biological considerations include intra-tumor heterogeneity within samples (particularly 
for small biopsies and TURB samples) exclusion of necrotic areas and tissue biomarker 
changes observed over time and in response to therapy. 
Technical considerations include the appropriate use of the four FDA/EMA-ap-
proved PD-L1 assays that utilize different antibodies, platforms, and scoring algorithms 
[55]. 
Based on analytical studies for each assay, inter- and intra-observer agreement ap-
pear high. For the VENTANA PD-L1 (SP263) Assay (TC/IC ≥ 25%), inter- and intra-reader 
precision studies demonstrated overall, negative, and positive percent agreement (OPA, 
NPA, and PPA, respectively) of >90% [47]. For the VENTANA PD-L1 (SP142) Assay (IC ≥ 
5%), in UC samples, the inter-reader precision OPA was 88.8% and the intra-reader precision 
OPA was 93.6% [59]. For the PD-L1 IHC pharmDx 22C3 Assay (CPS10), inter- and intra-
reader OPA, NPA, and PPA were all >90% [60]. For the PD-L1 IHC pharmDx 28-8 Assay (TC 
≥ 1%), inter and intra-reader OPA, NPA, and PPA were all >90% [61]. 
There are differences between assays in terms of staining patterns and the ability to 
detect different PD-L1-expressing cell types. Different assays present with particular 
staining patterns, e.g., the VENTANA PD-L1 (SP142) Assay with an ant-like/dot-like gran-
ular staining pattern or the PD-L1 IHC pharmDx 22C3 with an overall weak staining in-
tensity (Table 1). However, staining characteristics or staining intensity are not included 
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in PD-L1 scoring. More importantly, PD-L1 assays can show different performances in 
detecting proportions of different PD-L1-expressing cell types. All FDA-approved assays 
show comparable performance in detecting ICs, but the VENTANA PD-L1 (SP142) Assay 
consistently detects lower proportions of PD-L1-expressing TCs by comparing the same 
tissue samples (although the staining intensity is very high with this assay). Moreover, 
while both VENTANA PD-L1 (SP263 and SP142) assays demonstrate a very strong stain-
ing intensity, the PD-L1 IHC pharmDx 22C3 Assay often presents with a very weak stain-
ing intensity. Variability can be reduced using automated stainers and standardized 
epitope retrieval steps. Differences in staining characteristics can variably impact the in-
terpretation of PD-L1 positivity. There are also several design specifications that should 
be considered for the different PD-L1 assays, such as the exclusion of plasma cells from 
scoring for the VENTANA PD-L1 (SP263) Assay, VENTANA PD-L1 (SP142) Assay, and 
the PD-L1 IHC pharmDx 22C3 Assay. The approved PD-L1 assays, including technical 
platforms, scoring algorithms, typical staining characteristics, and special considerations 
are summarized in Table 1. 
Harmonization of PD-L1 testing in UC remains incomplete at present. Currently, the 
FDA requires, and the EMA recommends, the use of locked assays that have been rigor-
ously validated for use with the manufacturer’s platforms [47,48]. However, interchange-
able PD-L1 assays and instruments would provide pathology laboratories with a more 
practical and cost-effective solution. The results of several studies indicate that the PD-L1 
IHC pharmDx 22C3, PD-L1 IHC pharmDx 28-8, and VENTANA PD-L1 (SP263) assays are 
similar [62]), and concordance studies have shown a high inter-assay correlation between 
the PD-L1 IHC pharmDx 22C3, PD-L1 IHC pharmDx 28-8, and the VENTANA PD-L1 
(SP263) assays [55], with the highest analytical similarity between the VENTANA PD-L1 
(SP263) Assay and pharmDx 22C3 Assay [48]. Further validation of interchangeability in 
larger prospective studies, ideally including samples from patients who have been treated 
with IO agents, is still needed. Recent data suggest that inter-assay discordances are more 
likely caused by biological or analytical variables than by antibody epitope [63]. Many 
pathology laboratories, especially in Europe, are interested in implementing their own 
laboratory-developed tests (LDTs). In the United States, prescription drug labels stipulate 
the use of an FDA-approved assay. In Europe, LDTs validated in accordance with the 
EMA regulations and concordance studies will be required to validate LDTs across insti-
tutions utilizing a reference standard. Changing regulation of devices in Europe will in-
crease the requirement for both manufacturers and independent laboratories developing 
LDTs. 
In addition to the proposed practice recommendations (Table 2), appropriate, timely, 
and ongoing training of pathologists remains very important. If possible, the pathology 
laboratory should participate in a quality assurance scheme such as the UK National Ex-
ternal Quality Assessment Service (UKNEQAS) [64] to ensure best practice. Frequent pro-
ficiency testing of pathologists can be used to recognize the “drift” of scoring over time 
and to reduce inter-reader variation. Pathologists should ideally be trained by the manu-
facturer or third party and take advantage of available online training tools (i.e., NEQAS, 
2019, College of American Pathologistsexternal quality assessment, CAP EQA, 2020 
[64,65]). Pathologists should assess the PD-L1 expression following the manufacturer’s 
“Interpretation Guide” to define a PD-L1 status at the algorithm cutpoint of interest. Reg-
ular scoring (e.g., 10 slides per month) maintains practice for a given algorithm and if the 
practice is limited; refresher training can be taken online. Additionally, the International 
Quality Network for Pathology (IQN Path) run an academic proficiency testing program 
for the assessment of pathologists’ and technologists’ accuracy of biomarker readout [66]. 
6. Reporting of Results 
We encourage communication between clinicians and pathologists to ensure a fast 
turnaround and high-quality test result is delivered. Evaluation of the tumor immune re-
sponse has become a standard part of pathology practice, and diagnostic surgical 
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pathology plays a fundamental role in informing prognosis, guiding IO therapy, and con-
ducting clinical trials (i.e., patient stratification). Therefore, we recommend the PD-L1 test 
form includes both clinician and pathologist input (Figure 2). 
The form allows the pathologist to provide a comprehensive report to the clinician, 
with PD-L1 status at specific cutpoints, and also the PD-L1 expression raw scores. This 
informs on eligibility for a pre-specified IO therapy and potential eligibility for alterna-
tives based on the PD-L1 expression. The PD-L1 result should be reported at the cutpoints 
associated with the therapeutic and a statement regarding eligibility, for example, “SP142, 
IC > 5%, eligible for atezolizumab.” The TC and IC expression should also be reported 
separately to allow the clinician to identify other suitable therapies and understand the 
extent of PD-L1 expression. It is important to remember that the denominators for the 
scoring algorithms vary and include those shown in Figure 2. 
7. Emerging Biomarkers in UC 
Evidence indicates that PD-L1 by itself may not be sufficient in predicting response 
to IO agents in metastatic UC [55]. There is growing interest in the potential predictive 
value of tumor mutational burden (TMB) status in conjunction with PD-L1 expression 
[43,67,68]. TMB (≥10 mutations per megabase (mut/Mb)) and PD-L1 expression may im-
prove the prediction of response to IO agents in some tumors, such as non-small cell lung 
cancer [69]. 
In the PURE-01 study of MIBC, pathologic response to neoadjuvant pembrolizumab 
was associated with PD-L1–positive (CPS ≥ 10%) or high TMB (median 11.4 mut/Mb) tu-
mors. Notably, there was no correlation between PD-L1 expression and TMB. The data 
suggest a meaningful cutoff for TMB of ≥15 mut/Mb. Post-therapy reductions in TMB sug-
gest that it may be a biomarker of resistance to IO therapy [29]. 
In the IMvigor211 trial of metastatic UC following platinum-based chemotherapy, 
exploratory analyses showed that TMB was an independent predictor of response to ate-
zolizumab [70]. In the first-line atezolizumab study, IMvigor130, TMB (>10 mut/Mb) was 
predictive for monotherapy benefit (HR 0.71); less so for the combination with chemother-
apy (HR 0.82). Survival in PD-L1–high, TMB–high patients was longer (HR 0.22), indicat-
ing that a combination of biomarkers can be superior for predicting patient benefit [43]. 
Comprehensive genomic profiling (whole-exome or whole-genome sequencing) is the 
gold standard method for TMB measurements, but high costs, long turnaround times, and 
high tissue sample requirements are limiting factors for routine use in diagnostic labora-
tories [71]. 
Targeted next-generation sequencing (NGS) of formalin-fixed, paraffin-embedded 
blocks is a more feasible approach, and these panels can also provide useful information 
regarding driver mutations. FDA-approved or authorized diagnostic assays for TMB 
measurement are the MSK-IMPACT and FoundationOne CDx. The mutational number 
defining TMB “high” appears to vary across cancer types, and there is unlikely to be a 
universal number that defines the likelihood of benefit from IO agents in all tumor types. 
TMB threshold of ≥10 mut/Mb, measured by FoundationOne CDx (equivalent to approx-
imately 200 mutations by whole-exome sequencing) in first-line patients with non-small 
cell lung cancer was the first established cutoff. Recently, the FDA approved the use of 
pembrolizumab in patients with TMB ≥ 10 mut/Mb in a pan-tumor approval, which did 
not include UC. The TMB threshold is 7.4 mut/Mb for the MSK-IMPACT panel and the 
median number of somatic mutations differs across tumor types. In an analysis of 11,348 
patients, microsatellite instability (determined using data from a commercially available 
NGS panel) was found to be high in 23 of 26 cancer types but not bladder cancer [72]. The 
overall rates of high microsatellite instability, high TMB, and PD-L1 positivity across all 
cancer types studied were 3.0%, 7.7%, and 25.4%; only 0.6% of the cases were positive for 
all three biomarkers [72]. These data, and the results of other studies, suggest the potential 
need to evaluate more than one individual biomarker to assess the efficacy of IO agents. 
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Gene expression analyses have been utilized to understand responses to IO therapy 
better, elucidate mechanisms of resistance, and provide the subclassification of UC tu-
mors. Analyses of gene expression profiles in the T cell-inflamed microenvironment have 
shown pan-tumor immune-related signatures that correlate with anti–PD-1 benefit, in-
cluding IFNγ-responsive genes related to antigen presentation, chemokines, cytolytic ac-
tivity, and adaptive immune resistance [73]. In MIBC, an increase in immune gene expres-
sion has been reported in lesions following neoadjuvant treatment with pembrolizumab, 
including those related to adaptive immunity and innate resistance to anti–PD-1 therapy 
[29]. 
UC has a high frequency of somatic mutations, with epigenetic changes and muta-
tions in chromatin remodeling genes being especially frequent [2]. Gene expression pro-
filing has been used to classify UC into different subtypes. Molecular screening using a 
64-gene panel has identified three distinct subtypes of MIBC (luminal, basal, infiltrated), 
predictive of disease-specific survival outcomes [74]. Furthermore, an international con-
sensus statement regarding MIBC subtypes identified six different molecular classes 
(three luminal subtypes, one stroma rich, one basal, and one neuronal/neuroendocrine-
like) [75]. The luminal subtype has been shown to have a poor response to IO agents [70], 
and a lower immune signature [76], compared with other subtypes. As mutations in the 
gene encoding the fibroblast growth factor receptor (FGFR) are enriched in the luminal 
subtype of UC [77], erdafitinib, a tyrosine kinase inhibitor of FGFR1-4, has been approved 
for the second-line treatment of metastatic UC based on antitumor activity shown in an 
open-label, phase 2 study [78]. 
Higher numbers of tumor-infiltrating lymphocytes may be correlated with PD-L1 
[79] and predictive of response to IO agents. Moreover, they may be considered to be 
prognostic in several tumor types and may soon become part of clinical practice/diagnos-
tic pathology; recent evidence suggests that new T-cell clones may enter the tumor to re-
place pre-existing, exhausted CD8+ T cells in response to IO therapy [80]. Identification of 
these new T-cell clones in treated tumors may aid in the understanding of responses to IO 
therapy. 
In an analysis of tumors from patients with metastatic UC who had received atezoli-
zumab [81], response to treatment was associated with a CD8+ T-cell phenotype and, to a 
greater extent, high TMB and lack of response were associated with TGFβ signaling in 
fibroblasts, which was found predominantly in tumors that showed exclusion of CD8+ T 
cells from tumor parenchyma. The results suggest that TGFβ limits antitumor immunity 
with IO agents by restricting T-cell infiltration into tumors. Furthermore, DNA damage 
response and repair alterations have been demonstrated to be independently associated 
with response to PD-1/PD-L1 blockade in patients with metastatic UC [82]. 
Although additional biomarkers, such as TMB, have shown promising results, they 
are not yet approved for predicting IO response. In the future, other biomarkers may need 
to be evaluated in conjunction with PD-L1 to improve its predictive utility. A master pro-
tocol to include novel biomarkers into the current recommendations for PD-L1 testing 
may include an integrated report on the available biomarkers of response to IO together 
with PD-L1 assessment results. This may provide the oncologist/urologist with more in-
sight into how a particular patient will respond to IO. A proposed workflow for evalua-
tion biomarkers in UC may be found in Figure 4. 




Figure 4. UC biomarkers workflow, which is an integrated platform to report PD-L1 and other biomarkers. Figure 4 illus-
trates a prospective integrated protocol for multiple biomarker testings on samples from patients with UC. The numbers 
of sections required are shown in blue. Ideally, in the future, step 1 testing would be combined with step 2 testing to 
accelerate information to the clinician and inform potential treatment. A minimum of two slides are required for PD-L1 
testing and tissue requirements for next-generation sequencing (NGS) may vary according to the testing platform used. 
8. Conclusions/Future Directions 
Only two IO agents are currently approved for the first-line treatment of cisplatin-
ineligible metastatic UC, but there are considerable differences between the companion 
diagnostic assays for these agents. Biomarker testing is not currently required for the sec-
ond-line treatment of metastatic UC, despite the approvals of five IO agents. Harmoniza-
tion of PD-L1 testing remains a need and is increasingly important as the use of IO agents 
expands to include earlier stages of bladder cancer. Pre-analytical and analytical stand-
ards are of great relevance to extract the highest value from PD-L1 assays. The interpreta-
tion and reporting of the results of PD-L1 assays require fluid communication between 
oncologists/urologists and pathologists. PD-L1 expression may change during treatment 
and/or progression of the disease and may be a mechanism of drug resistance, but PD-L1 
testing during the course of treatment is not routinely conducted. 
To improve the predictive utility of PD-L1, other biomarkers may need to be evalu-
ated in conjunction with PD-L1, necessitating the development of an integrated master 
protocol to guide clinicians and pathologists. It is likely that composite biomarker panels 
may become standard in the future. The challenges involved in developing this new 
standard will include costs, time, sample availability, and logistics. An additional poten-
tial challenge is that the percentage of patients positive using the composite scores may 
be low, making it harder to identify the most appropriate IO therapy. Further information 
will be required and will become available as the relationship between PD-L1 and molec-
ular biomarkers is currently being explored in several clinical trials. 
The evaluation of combination regimens with IO and non-IO agents will increase the 
complexity of biomarker testing. Digital pathology, including artificial intelligence (e.g., 
Flagship Biosciences AI-powered cTA platform), may be utilized to predict response to 
IO therapy in the future. In this era of personalized medicine, further understanding of 
PD-L1 and novel biomarkers in UC will help guide patient treatment and IO drug devel-
opment in the future. 
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